We’ve got a new federal bill to share with you this week along with several state legislative developments! Click here to get the latest in marijuana law reform.
Legislative sessions around the country are moving quickly with several already coming to a close. It’s important to stay updated on pending measures in your state because NOW is the time to contact your elected officials using our #TakeAction Center urging their support for marijuana law reform. Click here to get this week’s latest legislative highlights!
For almost 45 years, NORML chapters have been the driving force behind policy decisions regarding marijuana on the local, state level and federal level. Get involved today!
The administration of cannabis oil extracts high in cannabidiol reduces seizure frequency in children with intractable epilepsy, according to clinical data published online ahead of print in the journal Seizure. Investigators reported: “CBD treatment yielded a significant positive effect on seizure load. Most of the children (89 percent) reported reduction in seizure frequency. … In addition, we observed improvement in behavior and alertness, language, communication, motor skills and sleep.”
The director of the US National Institute on Drug Abuse (NIDA), Nora Volkow, believes that cannabidiol (CBD) – a nonpsychotropic cannabinoid – is “a safe drug with no addictive effects.”
The administration of oral cannabis extracts is associated with the mitigation of seizures in adolescents with epilepsy, according to clinical data published this month in the journal Epilepsy & Behavior. Authors reported that 57 percent of subjects showed some level of improvement in seizure control while 33 percent reported a greater than 50 percent reduction in seizure frequency.
Last week, in what is becoming a semi-annual mainstream media ritual, news outlets around the globe published sensational headlines alleging that consuming cannabis will drives people crazy.
The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, is associated with improved quality of life in patients with Parkinson’s disease, according clinical trial data published online ahead of print in the Journal of Psychopharmacology. Authors reported that the administration of 300 mg doses of CBD per day was associated with “significantly different mean total scores” in subjects’ well-being and quality of life compared to placebo.
Most of us were caught off-guard by the rush of states this year that approved the limited use of CBD-only marijuana extracts because these traditionally conservative states had heretofore rejected the medical use of marijuana. So it seems worth a moment to consider how this occurred, and what it means on a grander scale. But first, a little recent history. Throughout this year’s state legislative season, a total of 10 states enacted laws seeking to provide limited access to medical marijuana products that contain high levels of CBD and virtually […]
Lawmakers in some half-dozen states are poised to enact cannabidiol-specific legislation. But will these measures ultimately help patients?